Endocyte Announces Phase 3 Vision Trial Design Finalized for 177Lu-PSMA-617 Following End of Phase 2 Meeting with the FDA

177Lu-PSMA-617 is a radioligand therapeutic (RLT) that targets the prostate-specific membrane antigen (PSMA), present in approximately 80% of patients with metastatic castration-resistant prostate cancer (mCRPC). This phase 3 ready RLT, which has been used to treat over 300 patients in clinical studies to date, delivers the beta-emitting radioactive isotope lutetium (177Lu) to diseased cells with encouraging results thus far.

Endocyte technology

Our novel therapeutics are designed to precisely deliver potent cancer therapies directly to the site of disease. Paired with companion imaging agents, this approach allows us to select the appropriate patient for our therapy, treating their disease while sparing healthy tissues.

Watch our technology at work


Several of our SMDCs and companion imaging agents are currently in clinical trials for treatment of:

  • Prostate cancer
  • Advanced solid tumors

Learn more

* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.


In 2018, we will be initiating late-phase clinical trials for mCRPC patients and Phase 1 testing of our novel, adaptor-controlled CAR-T program.
Our pipeline

Current Pipeline

PSMA-617 *
CAR-T (Adaptor Controlled*)